<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="5377" end="5387" sStart="5314" offset="63" sid="r8.suggest.v.0765" wn="3" wnkey="suggest%2:32:02::" text="15% of all the case reports described symptomatology suggesting acutely disturbed thyroid function (eg, anorexia, fatigue, tremor, palpitations, nervousness, increased sweating, mood and/or sleep disturbance, memory and concentration disorders, emotional lability, altered bowel habit, depression)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="933" end="939" sStart="null" offset="313" sid="null" wn="5" wnkey="severe%5:00:00:critical:03" text="[ 4 ] The first randomised controlled trial of mefloquine prophylaxis in heterogeneous, non-immune Western travellers was published in 2001 and found that one-third of all mefloquine users reported neuropsychiatric adverse effects and 6% of all users reported at least one severe adverse event (defined as requiring medical advice)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="24682" end="24688" sStart="null" offset="266" sid="r11.severe.j.0376" wn="1" wnkey="severe%5:00:00:intense:00" text="It has been known for some years that mefloquine users who take co-medications are about 1.5 times more likely to experience an adverse drug event than those users who take no co-medications, and twice as likely to experience severe adverse drug events." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="10075" end="10081" sStart="null" offset="195" sid="r11.severe.j.0373" wn="1" wnkey="severe%5:00:00:intense:00" text="[ 5 ] A 20-year old French traveller, concurrently taking an oral contraceptive, had epileptic seizures in her sixth week of mefloquine prophylaxis, directly after 'severe exertion'." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="933" end="939" sStart="null" offset="313" sid="null" wn="1" wnkey="severe%5:00:00:intense:00" text="[ 4 ] The first randomised controlled trial of mefloquine prophylaxis in heterogeneous, non-immune Western travellers was published in 2001 and found that one-third of all mefloquine users reported neuropsychiatric adverse effects and 6% of all users reported at least one severe adverse event (defined as requiring medical advice)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="29293" end="29299" sStart="null" offset="111" sid="r11.severe.j.0377" wn="1" wnkey="severe%5:00:00:intense:00" text="Fluoroquinolones, such as sparfloxacin, of loxacin and ciprofloxacin, are increasingly prescribed in severe cases of traveller's diarrhoea, and have been associated with severe reactions in mefloquine users." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="10265" end="10271" sStart="null" offset="172" sid="r11.severe.j.0374" wn="1" wnkey="severe%5:00:00:intense:00" text="[ 5 ] It seems likely that in some mefloquine users dehydration will impose an added burden on the liver, and that this could contribute to a severe reaction to the drug." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="933" end="939" sStart="null" offset="313" sid="r11.severe.j.0371" wn="1" wnkey="severe%5:00:00:intense:00" text="[ 4 ] The first randomised controlled trial of mefloquine prophylaxis in heterogeneous, non-immune Western travellers was published in 2001 and found that one-third of all mefloquine users reported neuropsychiatric adverse effects and 6% of all users reported at least one severe adverse event (defined as requiring medical advice)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="933" end="939" sStart="null" offset="313" sid="null" wn="5" wnkey="severe%5:00:00:critical:03" text="[ 4 ] The first randomised controlled trial of mefloquine prophylaxis in heterogeneous, non-immune Western travellers was published in 2001 and found that one-third of all mefloquine users reported neuropsychiatric adverse effects and 6% of all users reported at least one severe adverse event (defined as requiring medical advice)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="29382" end="29388" sStart="null" offset="200" sid="r11.severe.j.0378" wn="5" wnkey="severe%5:00:00:critical:03" text="Fluoroquinolones, such as sparfloxacin, of loxacin and ciprofloxacin, are increasingly prescribed in severe cases of traveller's diarrhoea, and have been associated with severe reactions in mefloquine users." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="18076" end="18082" sStart="null" offset="280" sid="r11.severe.j.0375" wn="5" wnkey="severe%5:00:00:critical:03" text="Previous liver or thyroid disease, and concurrent insults to the liver (such as from alcohol, dehydration, an oral contraceptive pill, recreational drugs, and other drugs that can damage the liver) may be related to the development of many severe or prolonged adverse reactions to mefloquine." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="9513" end="9519" sStart="null" offset="26" sid="r11.severe.j.0372" wn="5" wnkey="severe%5:00:00:critical:03" text="She was dehydrated and in severe liver failure, with negative virology." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="30341" end="30352" sStart="null" offset="190" sid="r11.recommend.v.0473" wn="1" wnkey="recommend%2:32:01::" text="Accompanied by explicit advice to avoid alcohol, maintain good hydration, and use co-medications with caution, we believe that prophylactic mefloquine could be recommended to certain occupational subsets of travellers who carry out safety-critical tasks and who until now have been denied the use of this drug." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="1160" end="1170" sStart="null" offset="145" sid="r11.recommend.v.0067" wn="1" wnkey="recommend%2:32:01::" text="On the evidence from a case series published in 1992 by the manufacturer, Hoffmann-La Roche, the World Health Organisation (WHO) recommends that travellers with a personal or family history of seizures or manic-depressive illness should not take mefloquine prophylaxis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="1160" end="1170" sStart="null" offset="145" sid="r11.recommend.v.0067" wn="1" wnkey="recommend%2:32:01::" text="On the evidence from a case series published in 1992 by the manufacturer, Hoffmann-La Roche, the World Health Organisation (WHO) recommends that travellers with a personal or family history of seizures or manic-depressive illness should not take mefloquine prophylaxis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2458-2-6.anc" start="23112" end="23117" sStart="null" offset="0" sid="null" wn="2" wnkey="rapid%5:00:02:fast:01" text="Can mefloquine be given safely as a pre-travel loading dose, for &lt;b&gt;rapid&lt;/b&gt; induction of chemoprophylaxis?" />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2458-2-6.anc" start="23112" end="23117" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Can mefloquine be given safely as a pre-travel loading dose, for &lt;b&gt;rapid&lt;/b&gt; induction of chemoprophylaxis?" />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="7204" end="7209" sStart="null" offset="79" sid="r9.paper.n.0762" wn="5" wnkey="paper%1:10:02::" text="We discuss the possible significance of this later in this paper." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="19573" end="19579" sStart="null" offset="8" sid="r9.normal.j.0173" wn="3" wnkey="normal%3:00:03::" text="8 mU/1, normal range 0.35-6." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="15611" end="15617" sStart="null" offset="7" sid="r9.normal.j.0367" wn="3" wnkey="normal%3:00:03::" text="?g/ml, normal range 18." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="142" end="146" sStart="null" offset="99" sid="r9.late.j.0978" wn="1" wnkey="late%3:00:00::" text="Mefloquine was developed by the US Army and introduced for the treatment of malaria in the late 1970s." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="19556" end="19560" sStart="null" offset="114" sid="r10.high.j.0572" wn="1" wnkey="high%3:00:02::" text="[ 51 ] At four weeks her thyroid stimulating hormone (TSH) concentration was found to be very high (44." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="14503" end="14511" sStart="null" offset="42" sid="r11.function.n.0816" wn="2" wnkey="function%1:07:00::" text="[ 1 ] The effect of mefloquine on thyroid function appears not to have been investigated in any phase III or phase IV study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="15521" end="15529" sStart="null" offset="10" sid="r11.function.n.0513" wn="2" wnkey="function%1:07:00::" text="A thyroid function screen showed a raised serum thyroglobulin level (54" />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="19529" end="19534" sStart="null" offset="87" sid="r10.find.v.0693" wn="4" wnkey="find%2:32:00::" text="[ 51 ] At four weeks her thyroid stimulating hormone (TSH) concentration was found to be very high (44." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="4139" end="4144" sStart="null" offset="79" sid="r10.find.v.0515" wn="2" wnkey="find%2:39:02::" text="[ 26 ] An annotated bibliography of the 516 published reports can be found at http://www.liv.ac.uk/evidence." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="8345" end="8350" sStart="null" offset="17" sid="r10.find.v.0542" wn="2" wnkey="find%2:39:02::" text="[ 31 ] Takeshima found that of a cohort of healthy Japanese soldiers who took prophylactic mefloquine for 36 weeks without drinking alcohol, one-quarter developed symptoms compatible with liver pathology and four showed disturbed liver function." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="31281" end="31287" sStart="null" offset="81" sid="r8.family.n.0891" wn="4" wnkey="family%1:14:01::" text="Lobel et al consider that WHO's exclusion of people with a personal or family history of neuropsychiatric illness from taking mefloquine is based 'on limited evidence or theoretical concerns', and we believe their scepticism is justified." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="1214" end="1220" sStart="null" offset="199" sid="r8.family.n.0255" wn="4" wnkey="family%1:14:01::" text="On the evidence from a case series published in 1992 by the manufacturer, Hoffmann-La Roche, the World Health Organisation (WHO) recommends that travellers with a personal or family history of seizures or manic-depressive illness should not take mefloquine prophylaxis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2458-2-6.anc" start="7533" end="7539" sStart="null" offset="20" sid="r9.appear.v.0515" wn="1" wnkey="appear%2:39:00::" text="Mefloquine does not appear to cause florid signs of liver disease." />
  </sentences>
</list>